Biotech Values

[masterlongevity]

RA must not be adding very much in terms of revenue to Rituxan. as far as i've heard they havn't lost any market share in CLL or NHL, in fact i've heard they are still gaining in CLL and in NHL maintenance. for the life of me, i dont understand how those revenues only wwent up 6%. my guess is that RA is adding < 100M in revenues.